Multiple system atrophy, cerebellar type

Multiple system atrophy, cerebellar type (MSA-C), formerly known as sporadic olivopontocerebellar atrophy or the cerebellar variant of multiple system atrophy, is a progressive neurodegenerative disorder characterized primarily by cerebellar dysfunction. It is one of two main clinical subtypes of multiple system atrophy (MSA), the other being the parkinsonian type (MSA-P). MSA-C predominantly affects the cerebellum and its connections, leading to progressive cerebellar ataxia — difficulty with coordination, balance, and gait. Patients typically present with unsteady walking, slurred speech (cerebellar dysarthria), limb incoordination, and oculomotor abnormalities. As the disease progresses, autonomic nervous system dysfunction becomes prominent, including orthostatic hypotension (drops in blood pressure upon standing), urogenital dysfunction (urinary urgency, incontinence, erectile dysfunction), and constipation. MSA-C typically manifests in adulthood, with a mean age of onset in the mid-50s, though it can appear from the late 40s onward. The disease is relentlessly progressive, with a median survival of approximately 6 to 10 years from symptom onset. The underlying pathology involves the abnormal accumulation of alpha-synuclein protein in oligodendrocytes, forming glial cytoplasmic inclusions, which classifies MSA as a synucleinopathy alongside Parkinson disease and dementia with Lewy bodies. Neuronal loss and gliosis are prominent in the cerebellum, pons, and inferior olivary nuclei. There is currently no cure or disease-modifying therapy for MSA-C. Treatment is symptomatic and supportive. Orthostatic hypotension may be managed with midodrine, fludrocortisone, or non-pharmacological measures such as compression stockings and increased salt intake. Physical therapy and occupational therapy are important for maintaining mobility and function. Speech therapy can help manage dysarthria and swallowing difficulties. Urological symptoms may require pharmacological management or catheterization. Research into potential neuroprotective strategies is ongoing, but no treatment has yet been proven to slow disease progression.

Common questions about Multiple system atrophy, cerebellar type